NanoNewron in the News
NanoNewron Awarded $2.5 Million in NIH STTR Phase 2 Grant to Advance its Innovative NN-840 Alzheimer’s Disease Program
UNION, N.J., September 9, 2025 – NanoNewron, a biotechnology startup developing innovative, humanized biologics that cross the
blood-brain barrier (BBB) to treat central nervous system (CNS) neurodegenerative diseases based on research developed at Rutgers,
The State University of New Jersey, has been awarded a $2.5 million NIH STTR Phase 2 grant to advance its TNF-alpha inhibitor
program for Alzheimer’s disease.
- The $2.5 million in NIH STTR Phase 2 Grant allows NanoNewron to start IND-enabling activities for the NN-840 program with an IND
submission expected next year - This NIH grant award confirms the scientific and clinical potential of the innovative approach of NanoNewron to treat Alzheimer’s
disease - This STTR grant strengthens the collaboration between NanoNewron and Rutgers, The State University of New Jersey where
NanoNewron’s technology was initially developed
NanoNewron Appoints Industry Veteran Marco Taglietti, M.D., as Chief Executive Officer to Lead the Company and the Development of Their Promising Alzheimer’s Compound
UNION, N.J., March 4, 2025 – NanoNewron, a pioneering biotechnology company developing innovative, humanized biologics that cross the blood-brain barrier (BBB) to treat Alzheimer’s and other central nervous system (CNS) neurodegenerative diseases, announced today that Marco Taglietti, M.D., has been appointed Chief Executive Officer, effective February 1st, 2025.
NanoNewron and its Research to Advance the Treatment of Alzheimer’s Disease are Featured by Rutgers University Newsletters and on Rutgers Today
UNION, N.J., February 20, 2025 – NanoNewron, a pioneering biotechnology company developing innovative, humanized biologics that cross the blood-brain barrier (BBB) to treat central nervous system (CNS) neurodegenerative diseases, announced today that Rutgers, the State University of New Jersey, is featuring the Company’s pipeline and research activities on their newsletters and on Rutgers Today.
Sources:
Rutgers Today
Yahoo Finance – NanoNewron Press Release
NanoNewron Files Patents Covering Use of NewroBus Technology for a Variety of Neurodegenerative Conditions
UNION, N.J., December 16, 2024 – NanoNewron is focused on the delivery of biologicals to the brain with a lead therapeutic product (NN-841) targeting TNF-α in AD patients. Patent applications have been filed.
NanoNewron Awarded a Phase I STTR NIH Grant to Support Further Preclinical Studies of NewroBus™ Technology
UNION, N.J., February 15, 2023 – NanoNewron a company focused on the delivery of biologicals to the brain to address unmet needs of neurodegenerative conditions, has been awarded a Phase I STTR grant from the National Institutes of Health. This funding will support further investigation of NewroBus™ Technology.